Principal Financial Group Inc. Has $94.78 Million Holdings in GE HealthCare Technologies Inc. (NASDAQ:GEHC)

Principal Financial Group Inc. boosted its holdings in shares of GE HealthCare Technologies Inc. (NASDAQ:GEHC - Free Report) by 1.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,009,910 shares of the company's stock after purchasing an additional 19,010 shares during the period. Principal Financial Group Inc. owned about 0.22% of GE HealthCare Technologies worth $94,780,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Quent Capital LLC boosted its stake in GE HealthCare Technologies by 18.4% in the 3rd quarter. Quent Capital LLC now owns 766 shares of the company's stock valued at $72,000 after buying an additional 119 shares in the last quarter. Greenleaf Trust boosted its stake in shares of GE HealthCare Technologies by 1.7% in the 3rd quarter. Greenleaf Trust now owns 7,619 shares of the company's stock valued at $715,000 after purchasing an additional 124 shares in the last quarter. Westside Investment Management Inc. grew its holdings in shares of GE HealthCare Technologies by 32.0% in the 3rd quarter. Westside Investment Management Inc. now owns 516 shares of the company's stock worth $48,000 after purchasing an additional 125 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of GE HealthCare Technologies by 8.7% during the second quarter. EverSource Wealth Advisors LLC now owns 1,590 shares of the company's stock worth $135,000 after buying an additional 127 shares in the last quarter. Finally, Quarry LP increased its holdings in GE HealthCare Technologies by 28.3% during the 2nd quarter. Quarry LP now owns 594 shares of the company's stock valued at $46,000 after purchasing an additional 131 shares in the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

GE HealthCare Technologies Stock Performance

Shares of GE HealthCare Technologies stock traded up $1.48 during trading on Friday, hitting $78.91. 11,179,275 shares of the stock were exchanged, compared to its average volume of 3,089,521. GE HealthCare Technologies Inc. has a 1-year low of $71.31 and a 1-year high of $94.55. The company has a current ratio of 1.23, a quick ratio of 0.98 and a debt-to-equity ratio of 1.12. The stock has a market capitalization of $36.05 billion, a price-to-earnings ratio of 21.68, a price-to-earnings-growth ratio of 2.96 and a beta of 1.07. The company has a fifty day moving average price of $84.64 and a 200-day moving average price of $83.72.

GE HealthCare Technologies (NASDAQ:GEHC - Get Free Report) last released its quarterly earnings data on Wednesday, October 30th. The company reported $1.14 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.06 by $0.08. The company had revenue of $4.86 billion during the quarter, compared to analysts' expectations of $4.87 billion. GE HealthCare Technologies had a return on equity of 25.19% and a net margin of 8.56%. The business's revenue was up .9% on a year-over-year basis. During the same period last year, the firm posted $0.99 earnings per share. As a group, equities analysts predict that GE HealthCare Technologies Inc. will post 4.3 EPS for the current fiscal year.

GE HealthCare Technologies Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 14th. Stockholders of record on Tuesday, January 14th will be given a $0.035 dividend. The ex-dividend date of this dividend is Tuesday, January 14th. This is a positive change from GE HealthCare Technologies's previous quarterly dividend of $0.03. This represents a $0.14 annualized dividend and a dividend yield of 0.18%. GE HealthCare Technologies's dividend payout ratio is presently 3.85%.

Analysts Set New Price Targets

A number of analysts recently weighed in on GEHC shares. Evercore ISI raised their price target on shares of GE HealthCare Technologies from $98.00 to $102.00 and gave the company an "outperform" rating in a report on Tuesday, October 1st. Wells Fargo & Company increased their target price on shares of GE HealthCare Technologies from $95.00 to $96.00 and gave the stock an "overweight" rating in a report on Thursday, October 31st. JPMorgan Chase & Co. initiated coverage on shares of GE HealthCare Technologies in a research report on Monday, September 9th. They issued a "neutral" rating and a $90.00 price objective for the company. BTIG Research upgraded GE HealthCare Technologies from a "neutral" rating to a "buy" rating and set a $100.00 price target for the company in a report on Wednesday, September 18th. Finally, Stifel Nicolaus upped their price objective on GE HealthCare Technologies from $100.00 to $102.00 and gave the stock a "buy" rating in a research report on Monday, September 30th. One analyst has rated the stock with a sell rating, four have given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $95.46.

Insider Transactions at GE HealthCare Technologies

In related news, CEO Roland Rott sold 3,577 shares of GE HealthCare Technologies stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $86.48, for a total transaction of $309,338.96. Following the completion of the sale, the chief executive officer now directly owns 24,298 shares of the company's stock, valued at approximately $2,101,291.04. This trade represents a 12.83 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.27% of the stock is currently owned by corporate insiders.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.